SK-N-SH Xenograft Model Overview

The SK-N-SH xenograft model is derived from a human neuroblastoma and is widely recognized for its utility in modeling neuronal tumor biology, heterogeneity, and therapeutic response in pediatric cancers. Originating from a metastatic bone marrow aspirate of a 4-year-old female patient with neuroblastoma, the SK-N-SH cell line displays a mixed phenotype composed of both neuroblastic (N-type) and substrate-adherent (S-type) cells. This heterogeneity reflects the variable differentiation states observed in clinical neuroblastoma, making the SK-N-SH xenograft model highly relevant for studies investigating cell lineage plasticity, tumor evolution, and therapeutic resistance.

In vivo, SK-N-SH xenografts form moderately aggressive tumors that recapitulate the histological and molecular diversity of human neuroblastoma. The model is particularly well suited for evaluating differentiation therapies, epigenetic modulators, and targeted agents that exploit the vulnerabilities of MYCN-non-amplified tumors. Its reproducible growth characteristics and multipotent phenotype provide a valuable system for studying tumor microenvironment interactions, stromal engagement, and mechanisms of minimal residual disease.

Request a Custom Quote for SK-N-SH Xenograft Model

Biological and Molecular Characteristics

The SK-N-SH cell line exhibits distinct morphological and molecular heterogeneity, with neuroblastic cells expressing markers of neuronal differentiation and adherent cells showing fibroblast-like features. Importantly, SK-N-SH is non-MYCN-amplified, distinguishing it from more aggressive, high-risk neuroblastoma models. The cell line expresses a range of neuronal markers including tyrosine hydroxylase (TH), β-III tubulin (TUBB3), and neuron-specific enolase (NSE). S-type cells contribute to extracellular matrix remodeling and tumor stability through expression of vimentin, fibronectin, and MMPs.

The p53 pathway is functional but partially attenuated, and the cell line harbors mutations affecting the RAS-MAPK axis, including NRAS and ALK variants in some subclones. Signaling through PI3K/AKT and ERK1/2 is elevated, supporting tumor proliferation and survival. Epigenetically, SK-N-SH expresses high levels of HDAC1, EZH2, and DNMT1, contributing to transcriptional repression and phenotypic plasticity.

Characteristic	SK-N-SH Profile
Tumor Type	Human neuroblastoma
Origin	Bone marrow metastasis (female, age 4)
MYCN Amplification	Absent
Neuronal Markers	TH+, TUBB3+, NSE+, NeuN+
Mesenchymal Markers	Vimentin+, Fibronectin+, MMP-2/9+
PI3K/AKT & MAPK Signaling	Elevated
ALK Status	Wild-type or mutated (depending on subclone)
p53 Status	Functionally expressed
Epigenetic Regulators	HDAC1+, EZH2+, DNMT1+
Morphology	Mixed N-type (neuronal) and S-type (stromal-like)

This multipotent and transcriptionally plastic phenotype supports wide-ranging applications in neuroblastoma biology, particularly for targeting lineage transition and treatment resistance.

In Vivo Model Development and Tumorigenicity

SK-N-SH xenografts are typically established in immunodeficient mice (e.g., athymic nude, NOD/SCID) via subcutaneous injection of 5 × 10^6 to 1 × 10^7 cells suspended in Matrigel. Tumor take rates exceed 85%, with palpable masses forming within 10–14 days and progressing to endpoint volumes (1,200–1,500 mm³) in 4–5 weeks. Growth is consistent and moderately aggressive, making it suitable for multi-arm therapeutic studies.

While subcutaneous models are most commonly used, orthotopic implantation into the adrenal gland or kidney capsule has been successfully performed to replicate the native tumor environment. These orthotopic models support studies of organ-specific invasion, vascular infiltration, and metastatic spread, particularly to the liver and lungs.

SK-N-SH xenografts are compatible with luciferase tagging, bioluminescent imaging, and ex vivo analysis of residual disease and stem-like cell populations. Because of their cellular heterogeneity, they are also used in lineage-tracing experiments and single-cell RNA sequencing studies.

Request a Custom Quote for SK-N-SH Xenograft Model

Histopathology and Immunohistochemical Profile

Histologically, SK-N-SH xenografts present with biphasic architecture, reflecting the coexistence of N-type and S-type cells. Neuroblastic areas contain small round blue cells with hyperchromatic nuclei and scant cytoplasm, while stromal-like areas consist of spindle-shaped cells arranged in fascicles. Tumors show moderate cellularity, occasional rosette formation, and low necrotic burden.

Immunohistochemical analysis reveals strong expression of β-III tubulin, TH, and NeuN in neuronal regions, while vimentin and fibronectin localize to stromal components. Ki-67 proliferation index ranges from 35–50%, indicating a moderate growth rate. Tumors also express ALK, HDAC1, and EZH2, supporting their use in epigenetic therapy studies. Vasculature is moderate, with CD31-positive vessels distributed throughout the tumor parenchyma.

This histological diversity makes SK-N-SH ideal for modeling tumor heterogeneity, lineage interconversion, and stromal modulation in neuroblastoma.

Preclinical Applications and Drug Response

The SK-N-SH xenograft model is extensively used for evaluating differentiation-inducing agents, such as retinoic acid (RA) and HDAC inhibitors, which promote neuronal lineage stabilization. It also serves as a valuable system for testing non-MYCN-targeted therapies, including ALK inhibitors, MEK inhibitors, and PI3K/AKT pathway antagonists. Given the intact p53 axis, SK-N-SH responds to genotoxic agents like doxorubicin and etoposide, although resistance can develop through epigenetic silencing.

The model is ideal for studies involving tumor microenvironment interactions, cell–matrix remodeling, and transcriptional reprogramming, especially in the context of relapse and minimal residual disease. Its biphasic nature supports screening strategies that aim to suppress mesenchymal transition or selectively target stromal-tumor crosstalk.

In orthotopic settings, SK-N-SH has been used to investigate metastatic mechanisms, immune evasion, and CNS involvement, while subcutaneous models remain the standard for initial compound screening and dose optimization.

Request This Model

To request the SK-N-SH xenograft model or incorporate it into studies of neuroblastoma heterogeneity, differentiation therapy, or lineage transition, please use the custom quote request link below. We support subcutaneous and orthotopic implantation protocols, as well as customized timelines and biomarker integration strategies.

Request a Custom Quote for SK-N-SH Xenograft Model